Arbutamine, a new potent non-selective /?-adrenoceptor agonist with mild ai-sympathomimetic activity, has been developed specifically for pharmacological stress testing. The drug acts like physical exercise, increasing both heart rate and myocardial contractility. Sensitivity, specificity and accuracy in detecting significant stenotic coronary artery disease are 76%, 96%, and 82%, respectively, again similar to those of exercise echocardiography.
Introduction
Stress echocardiography has emerged as a widely accepted new tool in the diagnosis of stenotic coronary artery disease. It is used for the detection of significant coronary artery stenosis, for risk stratification following myocardial infarction and before non-cardiac surgery, and for deciding when to use cardiac interventions, such as coronary artery bypass grafting and percutaneous transluminal coronary angioplasty.
Exercise in the form of treadmill or bicycle ergometry is still the most commonly used cardiac stress modality. However, about 20-40% of patients with suspected or known coronary artery disease are unable to exercise adequately or to reach the stress test endpoints because of coexisting peripheral vascular, orthopaedic or neurological disease 1 ' 1 . Motion artefacts during physical exercise and poor compliance to achieve sufficient workload are further limits.
These limitations have led to the development of pharmacological stress agents which stimulate the haemodynamic effects of exercise to induce myocardial ischaemia' 21 . The drugs most in use are dobutamine and the coronary vasodilators dipyridamole and adenosine. Now the new catecholamine arbutamine is available.
Dobutamine is a synthetic catecholamine with a strong positive inotropic and a less pronounced positive
Correspondence: Dr T. Ketteler. KJinikum Wuppertal GmbH, Medizinische KJinik B, Schwerpunkt Kardiologie, Heusnerstr. 40, 42283 Wuppertal, Germany. chronotropic action. It increases myocardial oxygen consumption predominantly by increasing myocardial contractility and to a lesser extent heart rate; arterial blood pressure does not significantly change' 2 ' 3 '. Dipyridamole causes coronary artery dilatation by increasing plasma levels of adenosine. In patients with significant stenosed coronary arteries, this leads to heterogeneity of blood flow with subsequent 'vertical' and 'horizontal' steal. The resulting decrease in oxygen supply causes myocardial ischaemia, which appears as wall motion abnormality and can be detected by echocardiography.
Adenosine can be given instead of dipyridamole. The mechanism of action and haemodynamic effects are the same, but with adenosine the vasodilating effect has a rapid onset and offset and the elimination half-life is less than 10 s. Numerous studies have demonstrated the high diagnostic accuracy of these agents in detecting coronary artery disease. The published literature shows that the overall sensitivities of dobutamine, dipyridamole and adenosine range from 54-96%, 57-75%, and 40-85%, respectively, while the corresponding specificities range from 66-95%, 80-100%, and 87-100% [4] . While dobutamine appears to be most sensitive in identifying significant single-vessel disease, no significant differences in efficacy were found with the detection of multivessel disease. Nevertheless, currently used pharmacological stress agents have limitations: they have to be administered stepwise at increasing dosages at certain time intervals, and no individual dose titration regimen is available.
The main contraindications in the use of dobutamine as a stress agent are the occurrence of ventricular tachyarrhythmias, hypertrophic cardiomyopathy, aortic stenosis and other left ventricular outflow obstructions, and severe hypertension. The incidence of serious side-effects is low, and arrhythmias occur in 10-35% of patients 1671 . Dipyridamole appears to be safe; severe adverse events are reported in 1-2% of patients' 51 , but it is contraindicated in obstructive lung disease, symptomatic hypotension and severe intraventricular conduction disturbances. Its reliability as a test may be hampered by ingestion of xanthine-containing food, drinks or drugs. Besides, some patients fail to reach target heart rate; however, the addition of atropine helps to increase heart rate and thereby to enhance the sensitivity of the test without lowering specificity'
891
. Unfortunately, atropine must not be administered in cases of glaucoma and prostatic enlargement.
Because of these limitations, what is wanted is a pharmacological stress agent capable of inducing myocardial ischaemia by increasing myocardial oxygen demand in a similar fashion to that obtained with exercise. The agent should be well tolerated and equal or even superior to the currently available stressors with respect to accuracy and predictive value for severe cardiac events in patients with coronary artery disease. Moreover, side effects should be negligible' 10 '. Arbutamine has been newly developed as a sympathomimetic agent for use in stress echocardiography.
Pharmacology
Arbutamine (Gensia, Inc., San Diego, CA, U.S.A.) is a synthetic mixed /?i+2 adrenoceptor agonist with mild affinity for ai-adrenoceptors'" 1 . It exhibits balanced chronotropic and inotropic responses. The resulting haemodynamic profile resembles that of patients during physical exercise, in that inotropic and chronotropic properties are relatively balanced: heart rate and contractility rise in parallel.
Arbutamine displays 10-fold greater affinity for /Preceptors and five-fold lower binding at the a-receptor level compared with dobutamine. It has a rapid onset and offset of action, exhibiting an initial effect within 1-2 min. The plasma half-life is approximately 8 min, the pharmacodynamic half-life, i.e. the time to 50% decrease in heart rate from the maximal response is 13-16 min.
In conscious anaesthetized dogs, arbutamine produces dose-dependent increases in heart rate, cardiac output, left ventricular systolic pressure, and left ventricular dP/dt, while mean arterial pressure falls slightly'" 1 . In healthy volunteers, arbutamine causes a dose-related increase in heart rate and systolic blood pressure. There is a linear correlation between infusion rate and steady-state plasma concentration, as shown by Cremer et alP 2] .
The haemodynamic profiles of arbutamine and dobutamine are similar. However, at a given rise in heart rate, the increase in left ventricular dP/dt is significantly more pronounced with dobutamine than with arbutamine. Conversely, for any given level of inotropic stimulation, arbutamine has much stronger positive chronotropic effects than dobutamine. These differences may be important in detecting myocardial ischaemia and viability.
In animal models of myocardial ischaemia, dobutamine induces regional myocardial dysfunction only when a sufficient increase in heart rate is achieved'
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. Dogs with a positive inotropic response but no increased heart rate fail to develop myocardial dysfunction. Thus, tachycardia seems to be more important in provoking ischaemia than inotropic stimulation, probably as a result of decreasing diastolic coronary perfusion time'
141
. Therefore, while arbutamine may be more effective in inducing ischaemia, the more pronounced inotropic effect of dobutamine, which is achieved in staged lower doses without increasing heart rate seems to favour the detection of viable myocardium. However, there are no data yet comparing the efficacy of arbutamine and dobutamine to support this assumption.
Pre-clinical evaluation
In animal models of myocardial ischaemia, arbutamine and dobutamine were directly compared with respect to myocardial blood flow and induction of myocardial ischaemia' 15161 . Arbutamine was equally effective as exercise, but superior to dobutamine in inducing ischaemia. Following dobutamine, percent wall thickening was significantly increased both in ischaemic and normal coronary artery beds. In contrast, following arbutamine wall thickening increased in the normal bed but decreased in the ischaemic bed'
161
. This variation in action occurred independently of altered transmural myocardial blood flow and independently of differences in haemodynamic effects of either agent. With its underlying differences in mechanism, /?-adrenoceptor subtype selectivity may play an important role. Guth et al. suggested that arbutamine's superiority in detecting ischaemia may be due to its pronounced chronotropic activity'
151
. Another reason may be that dobutamine elicits a stronger inotropic response resulting in hyperkinetic wall motion in normal and occasionally even ischaemic myocardium'
171 . This might prevent the detection of new wall motion abnormalities in ischaemic heart disease.
Clinical validation

Methods
GenESA System To achieve reproducible and feasible stress tests with arbutamine, a proprietary computerized closed-loop system was developed that adjusts the infusion rate according to the feedback from the patient's heart rate response (Fig. 1) . The device consists of a computer, a single channel ECG, a non-invasive blood pressure monitor, an i.v. syringe pump, a display screen, a key pad, and a printer. To start the test, the physician has to enter several patient parameters and select the slope of heart rate increase (heart rate slope, range 4-12 beats . min~ ' . min~ ') and the maximal heart rate (heart rate target). Then an initial standard dose of 01 ug . k g " ' . min~ ' is administered for 1 min, and the heart rate response is measured. The device calculates the dosing regimen according to the actual heart rate and adjusts the infusion to achieve the target heart rate, with a maximum infusion rate of 0-8 ug. kg~' . min ~' and a maximum total dose of 10 ug . kg~'. The system automatically monitors the heart rate at 5-s and blood pressure at 2-min intervals during the test. When close to the heart rate target, the GenESA device automatically reduces the infusion rate, and then stops the infusion to prevent an overshoot of heart rate above the heart rate target. To maintain the target heart rate, a 'hold' feature can be programmed, and the heart rate kept to a maximum of 5 min for the purpose of image acquisition and patient evaluation.
Built-in audible and visual 'alerts' and 'alarms' can be activated in response to changes in heart rate, rhythm, and other clinical conditions that require attention. Moreover, alarms will stop drug if safety is a concern. After termination of the drug infusion, the patient is monitored until heart rate, rhythm and blood pressure normalize, and both electrocardiographic and echocardiographic signs of ischaemia disappear.
Generally, the infusion is stopped when one of the following endpoints is achieved: target heart rate, ischaemia as revealed by the ECG (> 2 mm ST-segment deviation) or echocardiography (new or worsened wall motion abnormality), significant arrhythmia, heart rate saturation (maximal heart rate response without reaching target heart rate), intolerable adverse events, maximal infusion rate or total dose.
Results
Arbutamine has been evaluated as an echocardiographic stress agent in several clinical trials. Data on its efficacy and safety in diagnosing significant coronary artery disease were usually assessed in direct comparison with data from exercise testing. In the studies presented in the literature, significant coronary artery disease was defined as a significant coronary artery stenosis of >50%, as revealed by the coronary angiogram'
18 " 22 ', or as a rest or a stress-induced wall motion abnormality when it was defined echocardiographically. Myocardial ischaemia was diagnosed if new or worsening stress-induced wall motion abnormalities occurred. The echocardiographic definition of coronary artery disease is problematic: as pre-existing wall motion abnormalities at rest are commonly the consequence of ischaemic heart disease, a high prevalence of this picture will increase sensitivity.
The sensitivity of arbutamine stress echocardiography for detection of coronary artery disease is comparable to exercise echocardiography 20 '. In spite of a lower heart rate and lower systolic blood pressure following arbutamine i.v., both arbutamine i.v. and exercise were effective at revealing qualitatively and quantitatively congruent wall motion scores, ejection fractions, and a peak systolic pressure/ and systolic volume index ratio. Cramer et al. evaluated the efficacy of the computerized closed-loop delivery of arbutamine in 70 patients with coronary artery disease [211 . Two infusion regimens were chosen with a low heart rate slope of 6 beats . min ~' . min " ' and a high one with 10 beats . min~' . min~'. Their propensity to myocardial ischaemia, as detected by the ECG, was 52% for the low slope and 51% for the high slope. The corresponding results with echocardiography were 83% and 79%, respectively. There were no significant differences in maximum heart rate or in the slope of heart rate changes in either group (Table 1) .
Arbutamine caused the systolic blood pressure to rise by 26% and 23% in either regimen (Table 1) . Using the high slope regimen, maximum heart rate and maximum systolic blood pressure were obtained 1 -4 min and 3-7 min earlier than with the low-slope regimen (14-1 vs 12-7 min and 18-5 vs 14-8 min, respectively). Correspondingly, the duration of infusion was significantly longer for the low-slope regimen (15-2 vs 12-3 min); the total doses administered in the low and high slope regimens were similar (3-3 ug . kg~ ' vs 3-4 ug . kg~ ').
No major adverse events occurred during the test period. Angina pectoris and ventricular arrhythmias were noted in up to 40% and 35% of patients, respectively. The safety system of alerts and alarms identified rapid changes in heart rate or blood pressure including 'paradoxic' hypotension accurately. In conclusion, arbutamine proved effective and safe for both heart rate slope regimens' 21 '.
/><0-001; RPP=rate-pressure product.
Recently, the results from various multicentre clinical (phase 3) trials in Europe and North America have been presented. The data confirm the high diagnostic accuracy of arbutamine stress testing using ECG, echocardiography or nuclear perfusion imaging' The specificity was determined in 54 patients with a low risk of coronary artery disease (group 2). A total dose of 3-58 ug. kg" 1 was administered in group 1, and of 4-62ug.kg~' in group 2. The arbutamine test lasted longer in group 2 (181 min) than in group 1 (16-4 min). Heart rate, systolic blood pressure, and rate pressure product increased significantly in both groups; the increase was significantly more pronounced with exercise than with arbutamine ( Table 2) .
The overall sensitivity of arbutamine for inducing myocardial ischaemia was 76%, and for detecting coronary artery disease 84%. In group 1, sensitivity was 79% for arbutamine and 77% for exercise. The sensitivity of diagnosing coronary artery disease in patients with both stress tests was 87% for arbutamine and 83% for exercise (Fig. 2) . The specificity of arbutamine echocardiography was 96%. Subgroup analyses revealed that the detection of ischaemia was similar among patients with single-, double-and triple-vessel coronary artery disease; there were no differences with respect to the degree of stenosis.
In 38% of patients the arbutamine test was terminated because target heart rate was attained, in 15% because maximum heart rate saturation was reached or ECG changes occurred, in 21% because of angina pectoris, and in 6% because of wall motion abnormalities. In 4% of patients the test was stopped because of hypotension or dyspnoea. No deaths or other serious adverse effects were observed during arbutamine administration.
The most common side effects were arrhythmias in 72% of patients in group 1 and 54% in the low risk group 2, in whom there was a low likelihood of coronary disease (Table 5 ). Few of them displayed severe arrhythmias, such as non-sustained ventricular tachycardia and complex ventricular tachyarrhythmias. ). Sensitivity was determined in 114 patients with angiographically documented coronary artery disease, and specificity was assessed in a separate study in 54 patients with a low likelihood of coronary artery disease. Additional studies are being conducted under a phase 3B/4 programme to further validate the clinical utility of the GenESA system. Currently, a multicentre, multinational study is under way in which the clinical utility and safety of the system in diagnosing coronary artery disease in patients with known or suspected coronary artery disease is evaluated (Gensia Study Protocol 0141). So far, more than 1000 patients have been included in 60 centres in the U.S.A. and Canada and at 26 sites in Europe.
All patients included in the study stop taking /?-blockers for >48 h, class I antiarrhythmic drugs are withheld for > 1 week and amiodarone for > 30 days before the stress test. In a subgroup of 21 patients included in our hospital, a total dose of 2-08 ± 0-89 ug. kg~' arbutamine was administered; overall test duration and total infusion duration were almost identical to reported data from previous arbutamine studies (1205 ±3-94 min vs 1207 ± 296 min, respectively) 12 ". Haemodynamic effects are shown in Table 3 . Heart rate, systolic blood pressure and rate-pressure product increased significantly; the increases were similar to reports by Cremer et al. and Cohen et a/. [2122] .
Mean times to reach maximum heart rate and maximum systolic blood pressure were 12-3 and CAD=coronary artery disease; CI=confidence intervals.
13-8 min, respectively, similar to the high heart rate slope regimen of the European Study Group' 19 '. The sensitivity for inducing myocardial ischaemia (71%) and for detecting coronary artery disease (82%) were also within the range of the data referred to above ( stress tests terminated because target heart rate was reached was almost identical. In contrast to our data, Cohen et al., terminated 21% of the stress tests because of angina pectoris and 15% because of electrocardiographic ischaemia, while only 6% of tests were terminated because of new or worsening wall motion abnormalities' 221 . 'Heart rate saturation' describes the phenomenon that despite increasing doses of arbutamine no further increases in heart rate are observed. In spite of analogous heart rate increases in both studies, saturation was observed much more often in our small study subgroup (29%) than in the study group of Cohen et al. (15%) . This phenomenon has also been described during dobutamine stress testing and seems to point to a limitation of /?-adrenoceptor stimulation or a reflex increase in parasympathetic tone' 8 " 25 '. Interestingly, despite this high percentage of patients without attained target heart rate, the overall diagnostic accuracy has been high; this phenomenon has also been described in dobutamine stress echocardiography 126271 .
In a subsequent analysis of the data from the International Arbutamine Study Group' 281 , Bach et al. found that 73 of 120 patients (61%) already had evidence of ischaemia at low stress, i.e. at 20 beats . min~' above baseline, while 88 (73%) had echocardiographic evidence of ischaemia at peak stress. Simultaneously, ejection fraction increased from 59% at rest to 72% at low stress without a further increase at peak stress. These results suggest that the maxima! inotropic effects of arbutamine and even ischaemia may occur at a dose lower than that required for reaching the target heart rate.
The side effects observed in our subset of the multicentre study protocol 0141 were similar to those reported previously (Table 5) .
Conclusions
The present review shows that arbutamine echocardiography is an accurate and safe alternative to exercise and dobutamine stress echocardiography in the diagnosis of myocardial ischaemia and coronary artery disease. Whether arbutamine is superior to dobutamine or as effective in diagnosing viable myocardium has to be evaluated in further investigations. The closed-loop delivery device facilitates individual dosing and monitoring of the patient and may thereby reduce personnel requirements and costs, although arbutamine and the GenESA system are still more expensive than other stress agents. However, in Europe it is still the only officially approved pharmacological stress echocardiography modality and therefore an important new tool for the evaluation of coronary artery disease.
